The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss drug.

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

It wasn't a marriage made in heaven. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers, and that direct access to Wegovy won't be available via NovoCare Pharmacy to Hims ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Novo Nordisk on Monday said it is ending its collaboration with Hims & Hers due to concerns about the telehealth company's sales and promotion of cheaper knock-offs of the weight loss drug Wegovy.

On April 29, Novo Nordisk (NVO 0.22%) and Hims & Hers Health (HIMS 0.67%) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on ...